FNY Managed Accounts’s Lipocine LPCN Stock Holding History

FNY Managed Accounts’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-29	Closed	-$1K	–	731
2017 Q4	$1K	Buy	+29	New	+$1.8K	﹤0.01%	586

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

FNY Managed Accounts's LPCN Position: Q1 2018 in Review

FNY Managed Accounts sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 29 shares — an estimated $1K sold.

FNY Managed Accounts first reported a position in LPCN in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

FNY Managed Accounts reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
FNY Managed Accounts sold 29 Lipocine shares in Q1 2018, an estimated $1K.
FNY Managed Accounts first reported a position in Lipocine in Q4 2017 and held it in 1 quarter.
FNY Managed Accounts's Lipocine position peaked at $1K in Q4 2017.
27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.